Carlos Abelleyra Cordero, CEO Spanish Latin America of Aspen Labs, describes the rapid development of Aspen’s operational capacity throughout the region, in line with the company’s ambition to ultimately establish itself as the commercial partner of choice of big pharma companies in Latin America. He also documents Aspen’s focus on organic growth and smaller, strategic acquisitions that can complement the current product portfolio, the growth prospects he identifies in Latin America and the main market trends in Mexico.
When we met with you in 2014, Latin America was a major growth engine for the Aspen group, displaying an impressive 112 percent growth of its regional sales. How has Aspen Latin America been developing over the last two years?
Excluding Venezuela, Aspen Latin America has been displaying double-digit growth rates over the last two years
